163 related articles for article (PubMed ID: 31146385)
1. Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway.
Szybowska P; Kostas M; Wesche J; Wiedlocha A; Haugsten EM
Cells; 2019 May; 8(6):. PubMed ID: 31146385
[TBL] [Abstract][Full Text] [Related]
2. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
3. EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2.
Wu Y; Chen Z; Ullrich A
Biol Chem; 2003 Aug; 384(8):1215-26. PubMed ID: 12974390
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.
Kim DH; Kwak Y; Kim ND; Sim T
Cancer Biol Ther; 2016; 17(1):65-78. PubMed ID: 26574622
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
6. Signaling by FGF Receptor 2, Not FGF Receptor 1, Regulates Myelin Thickness through Activation of ERK1/2-MAPK, Which Promotes mTORC1 Activity in an Akt-Independent Manner.
Furusho M; Ishii A; Bansal R
J Neurosci; 2017 Mar; 37(11):2931-2946. PubMed ID: 28193689
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis.
Park J; Park OJ; Yoon WJ; Kim HJ; Choi KY; Cho TJ; Ryoo HM
J Cell Biochem; 2012 Feb; 113(2):457-64. PubMed ID: 21928350
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
[TBL] [Abstract][Full Text] [Related]
9. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
10. Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells.
Tsuchioka M; Takebayashi M; Hisaoka K; Maeda N; Nakata Y
J Neurochem; 2008 Jul; 106(1):244-57. PubMed ID: 18363829
[TBL] [Abstract][Full Text] [Related]
11. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 2 phosphorylation on serine 779 couples to 14-3-3 and regulates cell survival and proliferation.
Lonic A; Barry EF; Quach C; Kobe B; Saunders N; Guthridge MA
Mol Cell Biol; 2008 May; 28(10):3372-85. PubMed ID: 18332103
[TBL] [Abstract][Full Text] [Related]
13. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening on an α-helix to β-strand switchable region of the FGFR2 extracellular domain revealed positive and negative modulators.
Diaz C; Corentin H; Thierry V; Chantal A; Tanguy B; David S; Jean-Marc H; Pascual F; Françoise B; Edgardo F
Proteins; 2014 Nov; 82(11):2982-97. PubMed ID: 25082719
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
Byron SA; Gartside MG; Wellens CL; Mallon MA; Keenan JB; Powell MA; Goodfellow PJ; Pollock PM
Cancer Res; 2008 Sep; 68(17):6902-7. PubMed ID: 18757403
[TBL] [Abstract][Full Text] [Related]
16. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.
Shukla V; Coumoul X; Wang RH; Kim HS; Deng CX
Nat Genet; 2007 Sep; 39(9):1145-50. PubMed ID: 17694057
[TBL] [Abstract][Full Text] [Related]
17. ERK-mediated phosphorylation of fibroblast growth factor receptor 1 on Ser777 inhibits signaling.
Zakrzewska M; Haugsten EM; Nadratowska-Wesolowska B; Oppelt A; Hausott B; Jin Y; Otlewski J; Wesche J; Wiedlocha A
Sci Signal; 2013 Feb; 6(262):ra11. PubMed ID: 23405013
[TBL] [Abstract][Full Text] [Related]
18. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation.
Lew ED; Bae JH; Rohmann E; Wollnik B; Schlessinger J
Proc Natl Acad Sci U S A; 2007 Dec; 104(50):19802-7. PubMed ID: 18056630
[TBL] [Abstract][Full Text] [Related]
20. Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations.
Lorenzi MV; Castagnino P; Chen Q; Chedid M; Miki T
Oncogene; 1997 Aug; 15(7):817-26. PubMed ID: 9266968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
